https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-27 / 2016 Feb;5(2):e1078057
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-27 / 2016 Feb;5(2):e10780572015-08-27 00:00:002015-08-27 00:00:00Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-13 / Clin Transl Oncol 2016 Jan;18(1):82-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-13 / Clin Transl Oncol 2016 Jan;18(1):82-72015-08-13 00:00:002015-08-13 00:00:00Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-02 / Front Immunol 2015;6:271
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-02 / Front Immunol 2015;6:2712015-06-02 00:00:002015-06-02 00:00:00Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-28 / Immunotherapy 2015;7(8):855-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-19 / Radiother Oncol 2015 Nov;117(2):217-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-19 / Radiother Oncol 2015 Nov;117(2):217-222015-05-19 00:00:002015-05-19 00:00:00Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: Results in 248 patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-23 / Swiss Med Wkly 2015;145:w14133
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-23 / Swiss Med Wkly 2015;145:w141332015-04-23 00:00:002015-04-23 00:00:00Hyperthermia and reirradiation for locoregional recurrences in preirradiated breast cancers: a single institutional experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-18 / Breast 2015 Aug;24(4):418-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-18 / Breast 2015 Aug;24(4):418-252015-04-18 00:00:002015-04-18 00:00:00Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-01 / Breast Care (Basel) 2015 Apr;10(2):109-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-01 / Breast Care (Basel) 2015 Apr;10(2):109-162015-04-01 00:00:002015-04-01 00:00:00Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-02 / Biomed Res Int 2015;2015:127828
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-02 / Biomed Res Int 2015;2015:1278282015-03-02 00:00:002015-03-02 00:00:00Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-01 / Int J Hyperthermia 2014 Aug;30(5):285-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-01 / Int J Hyperthermia 2014 Aug;30(5):285-942014-08-01 00:00:002014-08-01 00:00:00Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer
